# EDGAR Filing Document

**Accession Number:** 0001563568
**File Stem:** 0001437749-26-017803
**Filing Date:** 2026-5
**Character Count:** 143574
**Document Hash:** 278f79adbd80091327f10f7dac4f7d85
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-017803.hdr.sgml**: 20260519

**ACCESSION NUMBER**: 0001437749-26-017803

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 60

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260519

**DATE AS OF CHANGE**: 20260519

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Envirotech Vehicles, Inc.
- **CENTRAL INDEX KEY:** 0001563568
- **STANDARD INDUSTRIAL CLASSIFICATION:** MOTOR VEHICLE PARTS & ACCESSORIES [3714]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38078
- **FILM NUMBER:** 26999889

**BUSINESS ADDRESS:**
- **STREET 1:** 1215 GRAPHITE DRIVE
- **CITY:** CORONA
- **STATE:** CA
- **ZIP:** 92881
- **BUSINESS PHONE:** (951) 407-9860

**MAIL ADDRESS:**
- **STREET 1:** 1215 GRAPHITE DRIVE
- **CITY:** CORONA
- **STATE:** CA
- **ZIP:** 92881

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ADOMANI, INC.
- **DATE OF NAME CHANGE:** 20170525

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Adomani, Inc.
- **DATE OF NAME CHANGE:** 20121203

?xml version='1.0' encoding='ASCII'? adom20260331_10q.htm

[**Table of Contents**](#toc)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 10-Q**

------

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE QUARTERLY PERIOD ENDED March 31, 2026**

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to** 

**Commission File Number: 001-38078**

------

**ENVIROTECH VEHICLES, INC.**

**(Exact name of registrant as specified in its charter)**

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Delaware** | **46-0774222** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **(State or other jurisdiction of** | **(I.R.S. Employer** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **incorporation or organization)** | **Identification No.)** |

---

---

| |
|:---|
| **7510 Ardmore Street** |
| **Houston, TX 77054** |
| **(Address of principal executive offices, including zip code)** |
| **(870) 970-3355** |
| **(Registrant**'**s telephone number, including area code)** |
| **N/A** |
| **(Former name, former address and former fiscal year, if changed since last report)** |

---

------

**Securities registered pursuant to Section 12(b) of the Act:**<br>

---

| | | |
|:---|:---|:---|
|  | **Trading** | **Name of each exchange** |
| **Title of each class** | **Symbol(s)** | **on which registered** |
| **Common Stock, par value $0.00001 per share** | **EVTV** | **Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Smaller reporting company | ☒ |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the registrant's common stock, $0.00001 par value per share, as of May 18, 2026 was 12,930,719.

------

**ENVIROTECH VEHICLES, INC. AND SUBSIDIARIES**

**TABLE OF CONTENTS**

**FORM 10-Q FOR THE QUARTERLY PERIOD ENDED March 31, 2026**

---

| | |
|:---|:---|
|  | **PAGE** |
| [Special Note Regarding Forward-Looking Statements](#specialnote) | [1](#specialnote) |
| [**Part I. FINANCIAL INFORMATION**](#part1) | [**Part I. FINANCIAL INFORMATION**](#part1) |
| [Item 1. Financial Statements:](#item1fs) | [2](#item1fs) |
| [Unaudited Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025](#bs) | [2](#bs) |
| [Unaudited Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 2025](#income) | [3](#income) |
| [Unaudited Consolidated Statement of Stockholders' Equity for the Three Months Ended March 31, 2026 and 2025](#equity) | [4](#equity) |
| [Unaudited Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025](#cashflow) | [5](#cashflow) |
| [Notes to Unaudited Consolidated Financial Statements](#notes) | [6](#notes) |
| [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#item2mda) | [16](#item2mda) |
| [Item 3. Quantitative and Qualitative Disclosure about Market Risk](#item3qqd) | [21](#item3qqd) |
| [Item 4. Controls and Procedures](#item4controls) | [21](#item4controls) |
| [**Part II. OTHER INFORMATION**](#part2other) |  |
| [Item 1. Legal Proceedings](#item1legal) | [22](#item1legal) |
| [Item 1A. Risk Factors](#item1arisk) | [22](#item1arisk) |
| [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#item2unregistered) | [22](#item2unregistered) |
| [Item 3. Defaults Upon Senior Securities](#item3defaults) | [22](#item3defaults) |
| [Item 4. Mine Safety Disclosures](#item4mine) | [22](#item4mine) |
| [Item 5. Other Information](#item5other) | [22](#item5other) |
| [Item 6. Exhibits](#exhibits) | [23](#exhibits) |
| [Signatures](#sigs) | [24](#sigs) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; i

------

**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q (this "Quarterly Report") of Envirotech Vehicles, Inc., including its consolidated subsidiaries (the "Company," "we," "us," and "our") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or our future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "contemplate," "plan," "project," "forecast," "potential," "possible," "proposed," "should," "develop," "opportunity," "target," "outlook," "optimistic," "poised," "positioned," "maintain," "continue," "aim," "goal," "will" and "would" or the negatives of these terms or other comparable terminology intended to identify statements about the future.

You should not place undue reliance on forward-looking statements. The cautionary statements set forth in this Quarterly Report, including in "Risk Factors" and elsewhere, identify important factors, which you should consider in evaluating our forward-looking statements. These factors could cause actual results and events to differ materially from those expressed or implied in any forward-looking statement and include, among other things:

• our ability to generate demand for our products in order to generate revenue;

• our dependence upon external sources for the financing of our operations;

• our ability to effectively execute our business plan;

• our ability to successfully integrate and realize the benefits of strategic acquisitions;

• our ability and our suppliers' ability to scale our manufacturing and assembling processes effectively and quickly;

• our ability to manage our expansion, growth and operating expenses and reduce and adequately control the costs and expenses associated with operating our business;

• the potential impact of product recalls and product liability claims relating to the products we distribute and other litigation;

• our ability and our manufacturing partners' ability to navigate disruptions to the global supply chain and procure the raw materials, parts, and components necessary to produce our products on terms acceptable to us and our customers;

• our ability to obtain, retain and grow our customers;

• our ability to enter into, sustain and renew strategic relationships on favorable terms;

• our dependency on, and retention of, key personnel;

• our ability to achieve and sustain profitability;

• the impact of legislation and/or government regulation on our business and industry, including, without limitation, the status of government subsidies, rebates and economic incentives that support the development and demand for our products and services within our electric vehicles segment and our ability to obtain required governmental authorizations for the sale and distribution of our drones;

• our compliance with foreign laws and regulations related to the international expansion of our drone division;

• ongoing and anticipated changes in the U.S. political environment and changes to regulatory agencies;

• changes in trade policies and the imposition of tariffs and other trade barriers in the jurisdictions where we source our materials or sell our products;

• our ability to evaluate and measure our current business and future prospects;

• our ability to compete and succeed in highly competitive and evolving industries;

• our ability to respond and adapt to changes in technology;

• the cost and adequacy of insurance coverage and increases in the number of severity of insurance and claims expenses;

• our ability to protect our intellectual property and to develop, maintain and enhance strong brands;

• disruptions in our information technology systems, including, but not limited to, system failures, cyber-attacks, unauthorized physical or electronic access, or other natural or man-made incidents or disasters; and

• our ability to maintain compliance with the listing requirements of the Nasdaq Stock Market LLC ("Nasdaq") and the impact of any steps taken to maintain such compliance on our operations, stock price and future access to capital.

You should read this Quarterly Report and the documents that we reference elsewhere in this Quarterly Report completely and with the understanding that our actual results may differ materially from what we expect as expressed or implied by our forward-looking statements. Forward-looking statements are subject to a number of known and unknown risks, uncertainties, assumptions and other important factors, including, but not limited to, those discussed in Part I, Item 2 (Management's Discussion and Analysis of Financial Condition and Results of Operations) and in Part II, Item 1A (Risk Factors) of this Quarterly Report as well as in Part I, Item 1 (Business) and Item 1A (Risk Factors and Part II, Item 7 (Management's Discussion and Analysis of Financial Condition and Results of Operations) of our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the "SEC") on April 13, 2026. In light of the significant risks and uncertainties to which our forward-looking statements are subject, you should not place undue reliance on such forward-looking statements or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. These forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report regardless of the time of delivery of this Quarterly Report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this Quarterly Report.

Unless expressly indicated or the context requires otherwise, references in this Quarterly Report to "Envirotech," the "Company," "we," "our," and "us" refer to Envirotech Vehicles, Inc., a Delaware corporation, and our consolidated subsidiaries, unless the context indicates otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1

------

**PART I. FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**ENVIROTECH VEHICLES, INC. AND SUBSIDIARIES**

**CONSOLIDATED BALANCE SHEETS**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***March 31,*** | ***December 31,*** |
|  | ***2026*** | ***2025*** |
| ASSETS |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash and cash equivalents | $2013817 | $358966 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts receivable, net of allowance of $0 and $0 respectively |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Receivable from related party, net of allowance of $6,669 and $6,082 respectively | 1600621 | 1196253 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EPA fulfillment asset | 1342966 | 1503477 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses | 350264 | 237610 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other current assets | 1463648 | 188074 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current assets | $6771316 | 3484380 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Property and equipment, net | 2250904 | 475959 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Right-of-use asset | 1946326 | 485482 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other non-current assets | 221995 | 221995 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total assets | $11190541 | $4667816 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable | $5236044 | $3581715 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred revenue | 1544000 | 1544000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EPA contract liability | 5146066 | 5169691 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accrued liabilities | 2326942 | 2257953 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operating lease liability - short-term | 563475 | 229899 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Debt - current | 3492936 | 505759 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current liabilities | $18309463 | 13289017 |
| Long-term liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operating lease liability - long-term | 1057465 | 306904 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities | $19366928 | 13595921 |
| Stockholders' equity: |  |  |
| Preferred stock, 5,000,000 authorized, $0.00001 par value per share, none issued and outstanding as of March 31, 2026, and December 31, 2025 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common stock, 350,000,000 authorized, $0.00001 par value per share, 12,930,719 and 7,736,129 issued and outstanding as of March 31, 2026, and December 31, 2025, respectively | 130 | 78 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Additional paid-in capital | 108398866 | 103660277 |
| Accumulated deficit | (116575383) | (112588460) |
| Total stockholders' equity | $(8176387) | (8928105) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities and stockholders' equity | $11190541 | $4667816 |

---

*See Accompanying Notes to Unaudited Consolidated Financial Statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2

------

**ENVIROTECH VEHICLES, INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***For the Three Months Ended*** | ***For the Three Months Ended*** |
|  | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** |
| Sales, net | $2248621 | $590567 |
| Cost of sales | 2437233 | 471175 |
| Gross profit | $(188612) | $119392 |
| Operating expenses |  |  |
| General and administrative | 3572437 | 3603108 |
| Consulting |  | 46511 |
| Research and development | 10000 | 98398 |
| Goodwill impairment charge |  | 10103048 |
| Total operating expenses, net | 3582437 | 13851065 |
| Loss from operations | $(3771049) | $(13731673) |
| Other (expense)/income: |  |  |
| Interest income (expense), net | $50 | $10754 |
| Loss on conversion and changes in fair value of convertible notes and debentures | (106997) | (283793) |
| Other expense | (108927) | (31669) |
| Total other expense | $(215874) | $(304708) |
| Loss before income taxes | (3986923) | (14036381) |
| Income tax expense |  |  |
| Net loss | $(3986923) | $(14036381) |
| Net loss per share to common stockholders: |  |  |
| Basic and diluted | $(0.31) | $(6.44) |
| Weighted average shares used in the computation of net loss per share: |  |  |
| Basic and diluted | 12885523 | 2180528 |

---

*See Accompanying Notes to Unaudited Consolidated Financial Statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3

------

**ENVIROTECH VEHICLES, INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENT OF STOCKHOLDERS**' **EQUITY**

**Three Months Ended March 31, 2026 and 2025**

**(unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  | ***Additional*** |  |  |
|  | ***Common Stock*** | ***Common Stock*** | ***Paid-In*** | ***Accumulated*** | ***Stockholders'*** |
|  | ***Shares*** | ***Amount*** | ***Capital*** | ***Deficit*** | ***Equity*** |
| **Balance, December 31, 2025** | 7736129 | $78 | $103660277 | $(112588460) | $(8928105) |
| Common stock issued for cash | 4570837 | 46 | 2677044 |  | 2677090 |
| Common stock issued from convertible notes conversion | 623753 | 6 | 358652 |  | 358658 |
| Warrants issued in conjunction with debentures | *—* |  | 606921 |  | 606921 |
| Warrants issued as deferred financing costs | *—* |  | 1070464 |  | 1070464 |
| Stock based compensation | *—* |  | 25508 |  | 25508 |
| Net loss | *—* |  |  | (3986923) | (3986923) |
| **Balance, March 31, 2026** | 12930719 | $130 | $108398866 | $(116575383) | $(8176387) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  | ***Additional*** |  |  |
|  | ***Common Stock*** | ***Common Stock*** | ***Paid-In*** | ***Accumulated*** | ***Stockholders'*** |
|  | ***Shares*** | ***Amount*** | ***Capital*** | ***Deficit*** | ***Equity*** |
| **Balance, December 31, 2024** | 1987261 | $20 | $94383917 | $(73461474) | $20922463 |
| Common stock issued from convertible notes conversion | 323378 | 3 | 1738202 |  | 1738205 |
| Stock based compensation | *—* |  | 546576 |  | 546576 |
| Net loss | *—* |  |  | (14036381) | (14036381) |
| **Balance, March 31, 2025** | 2310639 | $23 | $96668695 | $(87497855) | $9170863 |

---

*See Accompanying Notes to Unaudited Consolidated Financial Statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4

------

**ENVIROTECH VEHICLES, INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** |
|  | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** |
| **Cash flows from operating activities:** |  |  |
| Net loss | $(3986923) | $(14036381) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| Depreciation and amortization | 64037 | 280684 |
| Gain on conversion and changes in fair value of convertible notes | 106997 | 283793 |
| Goodwill impairment charge |  | 10103048 |
| Stock based compensation expense | 25508 | 546576 |
| Changes in assets and liabilities: |  |  |
| Accounts receivable |  | 164541 |
| Receivable from related party | (404367) | (202663) |
| Cash outflow from fraudulent activity |  | (2249515) |
| Inventory |  | 167108 |
| Inventory deposits |  | (2675003) |
| EPA fulfillment asset | 160511 |  |
| Prepaid expenses | (112654) | 629596 |
| Other current assets | (205110) | 6875 |
| Other non-current assets and right-of-use assets | (334376) | 48876 |
| Accounts payable | 1341248 | 338031 |
| EPA contract liability | (23625) |  |
| Accrued liabilities | 68986 | 123006 |
| Deferred revenue |  | 2284415 |
| Other liabilities | (42330) | (30467) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash used in operating activities | $(3342098) | (4217480) |
| **Cash flows from investing activities:** |  |  |
| Purchase of property and equipment | $(1525900) | (176828) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash used in investing activities | $(1525900) | (176828) |
| **Cash flows from financing activities:** |  |  |
| Proceeds from issuance of common stock | $2677090 |  |
| Proceeds from issuance of debenture | 3815000 |  |
| Proceeds from issuance of convertible note |  | 2850500 |
| Proceeds from issuance of other debt | 109061 |  |
| Principal repayments on other debt | (78302) | (186089) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash provided by financing activities | $6522849 | 2664411 |
| Net change in cash, restricted cash and cash equivalents | 1654851 | (1729897) |
| Cash and cash equivalents at the beginning of the period | 358966 | 1941181 |
| Cash and cash equivalents at the end of the period | $2013817 | $211284 |
| Supplemental cash flow disclosures: |  |  |
| Cash paid for interest expense | $960 | $6234 |
| Common stock issued from convertible notes conversion | $358658 | $1738205 |
| Debt discount from warrants issued | $1070464 | $— |
| Capital expenditures unpaid on March 31, 2026 and March 31, 2025 | $313082 | $— |

---

*See Accompanying Notes to Unaudited Consolidated Financial Statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5

------

**ENVIROTECH VEHICLES, INC. AND SUBSIDIARIES**

**NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS**

***1.*** **Organization and Operations**

Envirotech Vehicles, Inc., including its consolidated subsidiaries (the "Company"), is a United States ("U.S.") distributor of *zero*-emission commercial vehicles and heavy capacity drones engineered for logistics, infrastructure, and precision agriculture applications worldwide. The Company's systems enable a cleaner, safer, and more efficient future for critical industrial operations.

***2.*** **Summary of Significant Accounting Policies**

***Basis of Presentation***—These unaudited consolidated financial statements are prepared pursuant to the rules and regulations of the SEC regarding interim financial reporting. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the Company's opinion, these unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary for the fair statement of the results for the interim periods. These unaudited financial statements should be read in conjunction with the Company's audited financial statements for the years ended *December 31, 2025* and *2024* included in the Company's Annual Report on Form *10*-K filed with the SEC on *April 13, 2026.* The results of operations for the *three* months ended *March 31, 2026* are *not* necessarily indicative of the results to be expected for the full year.

***Principles of Consolidation***—The accompanying financial statements reflect the consolidation of the financial statements of Envirotech Vehicles, Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.

***Use of Estimates***—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions ****that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *6*

------

***Going Concern***—The Company's financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company sustained significant losses and negative cash flows from operations and is dependent on the overall improvement of its operating activities as well as debt and equity financings to fund its operations. The Company incurred a net loss of $3,986,923 and $14,036,381 for the *three* months ended *March 31, 2026* and *2025,* respectively. Cash used in operating activities was $3,342,098 and $4,217,480 for the *three* months ended *March 31, 2026* and *2025,* respectively. Accumulated deficit was $116,575,383 and $112,588,460 as of *March 31, 2026* and *December 31, 2025,* respectively. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

The Company plans to grow and expand its operations and seek additional sources of capital to pay its contractual obligations as they come due. Failure to successfully continue to grow operational revenues could harm the Company's profitability and adversely affect the Company's financial condition and results of operations. Management believes that its future operating strategy will provide the opportunity to continue as a going concern as long as the Company is able to obtain additional financing; however, there is *no* assurance this will occur. The accompanying financial statements do *not* include any adjustments that might be necessary if the Company is unable to continue as a going concern.

***Fair Value of Financial Instruments***—The carrying values of the Company's financial instruments, including cash, accounts receivable and ****accounts payable approximate their fair value due to the short-term nature of these financial instruments. Accounting Standards Codification ("ASC") *820, Fair Value Measurements ,*("ASC *820"*) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or ,most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. It also establishes a *three*-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level *1:*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Observable inputs such as quoted prices in active markets;

Level *2:*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

Level *3:*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unobservable inputs that are supported by little or *no* market data and that require the reporting entity to develop its own assumptions.

The Company does *not* have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis other than the debenture and warrants disclosed in Note *4* - Debt, in which the Company has elected the fair value option for the debenture.

***Revenue Recognition***—The Company recognizes revenue from the sales of *zero*-emission electric vehicles and vehicle maintenance and inspection services and delivery of medical supplies to the customers of its related party. The Company recognizes revenue in accordance with ASC *606, Revenue from Contracts with Customers* ("ASC *606"*), which requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company recorded net revenue of $0 from the sale of electric vehicles for the *three* months ended *March 31, 2026.* The Company recorded net revenue of $2,248,621 for the *three* months ended *March 31, 2026* for the Company's medical supplies segment. The revenue is recognized upon final delivery of medical supplies to a *third*-party customer even though the contract to deliver the medical supplies is with a related party as that is when the performance obligation is fulfilled. One customer, a related party, accounted for 100% of the net revenue for the *three* months ended *March 31, 2026* for the Company's medical supplies segment. See Note *8* - Related Party Transactions for further disclosures.

In applying ASC *606,* the Company is required to:

(*1*) identify any contracts with customers;

(*2*) determine if multiple performance obligations exist;

(*3*) determine the transaction price;

(*4*) allocate the transaction price to the respective obligation; and

(*5*) recognize the revenue as the obligation is satisfied.

Product revenue primarily includes the sale of electric trucks and cargo vans. These sales represent a single performance obligation and revenue is recognized when the vehicle is delivered, the customer has accepted the vehicle and signed the appropriate documentation acknowledging receipt of the vehicle. At this time, revenue is recognized. Product revenue for the electric vehicles segment for the *three* months ended *March 31, 2026* was $0.

Other revenue for the electric vehicles segment for the *three* months ended *March 31, 2026* was $0.

Medical supply revenue is recognized at the point in time when control transfers to the *third*-party customer, which in this arrangement, occurs when the gowns are delivered.

***Cash and Cash Equivalents***—The Company considers all highly liquid investments purchased with an original or remaining maturity of *three* ****months or less to be cash equivalents. The recorded value of our cash and cash equivalents approximates their fair value. See Concentration of Credit Risk below in this Note.

***Marketable Securities***—The Company invests in short-term, highly liquid, marketable securities, such as U.S. Treasury notes, U.S. Treasury ****bonds, and other government-backed securities. The Company classifies these marketable securities as held-to-maturity, as the intent is *not* to liquidate them prior to the respective stated maturity date. The Company had no marketable securities at both *March 31, 2026* and *December 31, 2025.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *7*

------

***Accounts Receivable and Allowance for Doubtful Accounts***— The accounts receivable balance relates to the Company's electric vehicles segment. The Company establishes an allowance for bad debts through a review of several ****factors, including historical collection experience, current aging status of the customer accounts, and financial condition of its customers. The Company does *not* generally require collateral for its accounts receivable. The Company had trade accounts receivable of $0 as of *March 31, 2026* and a recorded allowance for doubtful accounts of $0, resulting in a net trade accounts receivable balance of $0. The Company had trade accounts receivable of $0 as of *December 31, 2025* and an allowance for doubtful accounts of $0, resulting in a net trade receivable balance of *$0.*

***Receivable from Related Party and Allowance for Doubtful Accounts***—The receivable from related party relates to the Company's medical supplies segment. The allowance for doubtful accounts is established by reviewing several factors, including historical collection experience, current aging of the customer account and financial condition of its customer. The Company had receivable from related party of $1,607,290 and a recorded allowance of $6,669, resulting in a net receivable from related party of $1,600,621 as of *March 31, 2026.* The Company had a receivable from related party of $1,202,335 and a recorded allowance of $6,082, resulting in a net receivable from related party of $1,196,253 as of *December 31, 2025.*

***Inventory and Inventory Valuation Allowance***—The Company records inventory at the lower of cost or market, and uses a First In, First Out valuation methodology and establishes an inventory valuation allowance for vehicles that it does *not* intend to sell in the future or when their cost has fallen below net realizable value. The Company had finished goods inventory on hand of $6,040,410 as of *March 31, 2026* and recorded an inventory valuation allowance of $6,040,410 related to vehicles that the Company does *not* intend to sell in the future, resulting in a net inventory balance of $0 at *March 31, 2026*. The Company had finished goods inventory on hand and a related inventory valuation allowance of $6,040,410 and $6,040,410, respectively, as of *December 31, 2025*, resulting in a net inventory balance of $0 as of *December 31, 2025.* 

***Inventory Deposits***—Certain of the Company's vendors require the Company to pay upfront deposits before they commence manufacturing its vehicles and then require progress deposits through the production cycle and before the finished vehicles are shipped. These deposits are classified as inventory deposits in the consolidated balance sheets. Upon completion of production acceptance by the Company, and passage of title to the Company from the inventory supplier, deposits are reclassified to inventory. The Company had inventory deposits of $0 and $0 as of *March 31, 2026* and *December 31, 2025*, respectively.

***EPA Fulfillment Asset***—These are costs incurred to fulfill the U.S. Environmental Protection Agency ("EPA") school bus contract that are capitalized. These costs will be expensed to cost of goods sold once all the performance obligations stipulated in the EPA school bus contract are satisfied and revenue from the contract is recognized. The balance of EPA fulfillment asset at *March 31, 2026* and *December 31, 2025* was $1,342,966 and $1,503,477, respectively.

***Other Current Assets***—At *March 31, 2026,* other current assets consist primarily of $1,070,464 of deferred costs associated with warrants granted in connection with the debentures further disclosed in Note *4* - Debt, Note *6* - Stock Warrants and Note *12* - Subsequent Events, as well as $365,159 of deferred costs attributable to services performed but *not* yet billable and the remaining balance of $28,025 consists of individually immaterial items.

***Income Taxes***—The Company uses the liability method, where deferred tax assets and liabilities are determined based on the expected future tax ****consequences of temporary differences between the carrying amounts of assets and liabilities for financial and income tax reporting purposes.

***Accounting for Uncertainty in Income Taxes***—The Company evaluates its uncertain tax positions and will recognize a loss contingency when it ****is probable that a liability has been incurred as of the date of the financial statements and the amount of the loss can be reasonably estimated. The amount recognized is subject to estimate and management judgment with respect to the likely outcome of each uncertain tax position. The amount that is ultimately sustained for an individual uncertain tax position or for all uncertain tax positions in the aggregate could differ from the amount recognized. At *March 31, 2026* and *December 31, 2025*, respectively, management did *not* identify any uncertain tax positions.

***Net Loss Per Share***—Basic net loss per share is calculated by dividing the Company's net loss applicable to ****common stockholders by the weighted average number of shares of common stock outstanding during the period. For the periods presented, the diluted loss per share and basic loss per share calculations are the same as the diluted loss per share calculation would be anti-dilutive.

Diluted net loss per share is calculated by dividing the Company's net loss applicable to common stockholders by the diluted weighted average number of shares of common stock outstanding during the period. The diluted weighted average number of shares of common stock outstanding is the basic weighted number of shares of common stock adjusted for any potentially dilutive debt or equity securities. As of *March 31, 2026*, 895,250 shares of the Company's common stock were subject to issuance upon the exercise of stock options then outstanding and 1,438,817 shares of the Company's common stock were subject to issuance upon the exercise of warrants then outstanding. As disclosed in Note *4* - Debt, 1,291,778 warrants with an exercise price of $0.01 per share of the Company's common stock were issued in conjunction with the Company's debenture financing. These warrants were included in the Company's basic net loss per share calculation as the warrants require the holder to pay little consideration to receive the shares upon exercise of the warrant.

***Concentration of Credit Risk***—The Company has credit risks related to cash and cash equivalents on deposit with a federally insured bank, as at times it exceeds the *$250,000* maximum amount insured by the Federal Deposit Insurance Corporation ("FDIC"). Additionally, the Company *may* maintain cash and short-term securities invested at Arvest Bank, National Association ("Arvest"). Between FDIC and the Securities Investor Protection Corporation ("SIPC") coverage, funds up to $750,000, which *may* include cash up to $500,000, are insured. In addition, Arvest provides excess insurance acquired by them from SIPC for unlimited per customer securities up to a $1 billion cap. There were *no* short-term securities invested at Arvest at *March 31, 2026.* Additionally, the Company had a concentration in accounts payable, as one vendor and two vendors made up greater than *10%* individually, and 42% and 54% in the aggregate of the outstanding accounts payable balance as of *March 31, 2026,* and *December 31, 2025,* respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *8*

------

***Impairment of Long-Lived Assets***—Long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset *may not* be recoverable. The Company evaluates these assets to determine potential impairment by comparing the carrying amount to the undiscounted estimated future cash flows of the related assets. If the estimated undiscounted cash flows are less than the carrying value of the assets, the assets are written down to their fair value. There was *no* impairment of long-lived assets, or property and equipment, as of *March 31, 2026* and *December 31, 2025,* respectively.

***Research and Development***—Costs incurred in connection with the development of new products and manufacturing methods are charged to operating expenses as incurred. Research and development costs were $10,000 and $98,398 during the *three* months ended *March 31, 2026* and *2025,* respectively.

***Stock-Based Compensation***—The Company accounts for employee stock-based compensation in accordance with the guidance of ****ASC *718,* Stock-Based Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. The fair value of the equity instrument is charged directly to compensation expense and credited to additional paid-in capital over the period during which services are rendered. Non-cash stock-based compensation expense of $25,508 and $546,576 was recorded for the *three* months ended *March 31, 2026* and *2025,* respectively.

***Property and Equipment***— Property and equipment are stated at cost, less accumulated depreciation. The Company provides for ****depreciation using the straight-line method over the estimated useful lives of the assets, which range from three to five years, except leasehold improvements, which are being amortized over the life of the lease term. Property and equipment qualify for capitalization if the purchase price exceeds *$2,000.* Major repairs and replacements, which extend the useful lives of equipment, are capitalized and depreciated over the estimated useful lives of the property. All other maintenance and repairs are expensed as incurred. See Note *3* - Property and Equipment, net.

***EPA Contract Liability***—These are amounts related to the EPA school bus program that are expected to be reimbursed to the EPA as a result of the Company's decision to discontinue the electric school bus initiative. The balance of EPA contract liability at *March 31, 2026* and *December 31, 2025* was $5,146,066 and $5,169,691, respectively.

***Leases***—The Company accounts for leases in accordance with ASC *842,* Leases ("ASC *842"*). At the inception or modification of a contract, the Company determines whether a lease exists and classifies its leases as an operating or finance lease at commencement. Right-of-use ("ROU") assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent their obligation to make lease payments arising from the lease. See Note *10* - Leases.

As most of the Company's leases do *not* provide an implicit interest rate, the lease liability is calculated at lease commencement as the present value of unpaid lease payments using the Company's estimated incremental borrowing rate. The incremental borrowing rate represents the rate of interest that the Company would have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term and is determined using a portfolio approach based on information available at the commencement date of the lease.

The lease asset also reflects any prepaid rent, initial direct costs incurred, and lease incentives received. The Company's lease terms *may* include optional extension periods when it is reasonably certain that those options will be exercised.

Leases with an initial expected term of *12* months or less are *not* recorded in the Company's consolidated balance sheets and the related lease expense is recognized on a straight-line basis over the lease term. For certain classes of underlying assets, the Company has elected to *not* separate fixed lease components from the fixed non-lease components.

***Recently Issued Accounting Pronouncements *Not* Yet Adopted***

**ASU *No. 2024*-*03,* "Income Statement (Subtopic *220*-*40*): Disaggregation of Income Statement Expenses"**

In *November 2024,* the Financial Accounting Standards Board issued ASU *2024*-*03,* Income Statement (Subtopic *220*-*40*): Disaggregation of Income Statement Expenses ("ASU *2024*-*03"*), which requires additional information about certain expenses in the notes to the financial statements. ASU *2024*-*03* is effective for fiscal years beginning after *December 15, 2026,* with early adoption permitted. The Company is currently evaluating the impact of adopting ASU *2024*-*03* and will adopt the guidance when it becomes effective on a prospective basis.

***3.*** **Property and Equipment, Net**

Components of property and equipment, net, consist of the following as of *March 31, 2026* and *December 31, 2025*:

---

| | | |
|:---|:---|:---|
|  | ***March 31,*** | ***December 31,*** |
|  | ***2026*** | ***2025*** |
| Furniture and fixtures | $125620 | $125620 |
| Leasehold improvements | 380286 | 380286 |
| Machinery and equipment | 377521 | 377521 |
| Vehicles | 387693 | 387693 |
| Construction in progress | 1838982 |  |
| Test/Demo vehicles | 30685 | 30685 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total property and equipment | 3140787 | 1301805 |
| Less accumulated depreciation | (889883) | (825846) |
| Property and equipment, net | $2250904 | $475959 |

---

Depreciation expense was $64,037 and $58,184 for the *three* months ended *March 31, 2026* and *2025,* respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *9*

------

***4.*** **Debt**

*<u>Notes Payable</u>*

On *July 15, 2022,* the Company entered into an equipment financing agreement with Wells Fargo Bank, N.A. in connection with the purchase of facility grounds equipment. The $25,007 loan is payable over 36 months, beginning in *August 2022,* with monthly payments of $521. The balance of this note was $2,605 as of *March 31, 2026,* of which $2,605 is classified as Notes Payable - current on the Company's unaudited condensed consolidated balance sheets as of *March 31, 2026*.

On *June 15, 2025,* the Company entered into a premium financing agreement with AFCO Insurance Premium Finance to finance its directors' and officers' insurance coverages. The $140,400 loan is payable over nine months, beginning in *July 2025,* and bears interest at 8.24% with monthly payments of $14,576. The balance of this note was $14,476 as of *March 31, 2026*.

On *August 28, 2025,* the Company entered into a premium financing agreement with AFCO Insurance Premium Finance to finance certain insurance coverages other than its directors' and officers' insurance coverages. The $114,140 loan is payable over eleven months, beginning in *September 2025,* and bears interest at 8.24% with monthly payments of $7,809 and an initial down payment of $39,515. The balance of this note, including accrued interest, was $76,359 as of *March 31, 2026.*

On *January 1, 2026,* the Company entered into a premium financing agreement with IPFS Corporation to finance certain insurance coverages. The $101,837 loan is payable over 11 months, beginning in *February 2026,* and bears interest at 7.90% with monthly payments of $7,214 and an initial down payment of $25,435. The balance of this note was $69,685 as of *March 31, 2026*.

*<u>Amended and Restated Standby Equity Purchase Agreement (the "A&R SEPA")</u>*

On *October 31, 2024,* the Company entered into A&R SEPA with YA II PN, Ltd. (the "Investor"). The A&R SEPA amends and restates in its entirety the standby equity purchase agreement, dated *September 23, 2024,* by and between the Company and the Investor (the "Original SEPA").

Pursuant to the A&R SEPA, except for so long as there is a balance outstanding under the Promissory Notes (as defined below) and the Additional Promissory Notes (as defined below), the Company has the right, from time to time, until *November 1, 2027,* to require the Investor to purchase up to $25 million of shares of common stock, subject to certain limitations and conditions set forth in the A&R SEPA, by delivering written notice to the Investor. Pursuant to the A&R SEPA, the Investor advanced to the Company the principal amount of $3 million (the "Pre-Paid Advance") in exchange for the Company's issuance to the Investor of convertible promissory notes (the "Promissory Notes") in *two* tranches, resulting in net proceeds (net of discounts and fees) to the Company of $2,635,500. The Company received the *first* tranche of the Pre-Paid Advance in the principal amount of $2 million on *October 31, 2024* in exchange for the Promissory Note dated *October 31, 2024 (*the "EVTV-*1* Promissory Note"), and the *second* tranche of the Pre-Paid Advance in the principal amount of $1 million on *December 17, 2024* in exchange for the Promissory Note dated *December 17, 2024 (*the "EVTV-*2* Promissory Note"). The Promissory Notes accrue interest on the outstanding principal balance at an annual rate equal to 0%, which would increase to an annual rate of 18% upon the occurrence of an Event of Default (as defined in the Promissory Notes) or a Registration Event (as defined in the Promissory Notes) for so long as such event of default remained uncured. Prior to the Company's entry into the Supplemental Agreement (as defined below), the Promissory Notes were initially set to mature on *November 13, 2025* and were convertible at a conversion price equal to the lower of (i) $21.48 per share or (ii) 93% of the lowest daily volume weighted average price of the Company's common stock on Nasdaq Stock Market LLC ("Nasdaq") as reported by Bloomberg L.P. ("VWAP") during the five consecutive trading days immediately preceding the conversion date (but *no* lower than the "floor price" then in effect, which was $3.58 per share, subject to adjustment from time to time in accordance with the terms contained in the Promissory Notes). Pursuant to the terms of the Original SEPA, the Company issued 6,410 shares of common stock to the Investor as a commitment fee.

During *2025,* the obligation under the EVTV-*1* Promissory Note was partially satisfied through the conversion of the EVTV-*1* Promissory Note into shares of the Company's common stock. As a result of this conversion, 1,416,116 shares of the Company's common stock were issued at a weighted average price of $1.06. The remaining principal balance of the EVTV-*1* Promissory Note at *December 31, 2025,* was $285,000. The remaining obligation was fully satisfied through the conversion of the EVTV-*1* Promissory Note into shares of the Company's common stock during the *first* quarter of *2026.* As a result of this conversion, 529,096 shares of the Company's common stock were issued at a weighted average price of $0.63.

The Company has elected to measure the Promissory Notes at fair value. In estimating the fair value of the Promissory Notes, a lattice model is applied. The required inputs include the current stock price, the term, the conversion price, the risk-free rate and volatility of the common stock. The Promissory Notes' fair values are classified as Level *3* under the fair value hierarchy as provided by ASC *820.*

<u>*Supplemental Agreement to A&R SEPA*</u>

On *February 24, 2025,* the Company entered into a supplemental agreement, dated *February 24, 2025 (*the "Supplemental Agreement"), with the Investor, which amends and supplements the A&R SEPA to: (i) provide for the advancement by the Investor to the Company, subject to the satisfaction of certain conditions as set forth in the Supplemental Agreement, of $5 million under the A&R SEPA (the "Additional Pre-Paid Advance"), to be evidenced by convertible promissory notes (the "Additional Promissory Notes") in *two* tranches, (ii) amend the maturity date for the EVTV-*1* Promissory Note to *March 9, 2026,* and (iii) amend the floor price for the EVTV-*1* Promissory Note to $0.7130 per share.

The Additional Promissory Notes accrue interest on the outstanding principal balance at an annual rate equal to 5%, which would increase to an annual rate of 18% upon the occurrence of an Event of Default (as defined in the Additional Promissory Notes) or a Registration Event (as defined in the Additional Promissory Notes) for so long as such event remained uncured. The Additional Promissory Notes were scheduled to mature on *March 9, 2026.* The Additional Promissory Notes were convertible at a conversion price equal to the lower of (i) $10.00 per share or (ii) 93% of the lowest daily VWAP during the five consecutive trading days immediately preceding the conversion date (but *no* lower than the "floor price" then in effect, which is $0.7130 per share, subject to adjustment from time to time in accordance with the terms contained in the Additional Promissory Notes).

The *first* tranche of the Additional Pre-Paid Advance was disbursed on *February 25, 2025* in the principal amount of $3 million (with net proceeds to the Company of approximately $2.7 million after deducting discounts and fees) as evidenced by an Additional Promissory Note issued by the Company to the Investor on *February 24, 2025 (*the "EVTV-*3* Additional Promissory Note"). During *2025,* the obligation under the EVTV-*3* Additional Promissory Note in the principal amount of $3 million was partially satisfied through the conversion of the EVTV-*3* Additional Promissory Note into shares of the Company's common stock. As a result of this conversion, 2,134,613 shares of the Company's common stock were issued at a weighted average price of $1.51. The remaining principal balance of the EVTV-*3* Additional Promissory Note on *December 31, 2025,* was $50,000. The remaining obligation was fully satisfied through the conversion of the EVTV-*3* Additional Promissory Note into shares of the Company's common stock during the *first* quarter of *2026.* As a result of this conversion, 94,657 shares of the Company's common stock were issued at a weighted average price of $0.53.

The Company has elected to measure the Additional Promissory Notes at fair value. In estimating the fair value of the Additional Promissory Notes, a lattice model is applied. The required inputs include the current stock price, the term, the conversion price, the risk-free rate and volatility of the Company's common stock. The Additional Promissory Notes' fair values are classified as Level *3* under the fair value hierarchy as provided by ASC *820.*

<u>*Debenture Financing*</u>

On *March 6, 2026,* the Company entered into a securities purchase agreement (the "SPA") with the Investor, pursuant to which the Company agreed to issue and sell to the Investor, and the Investor agreed to purchase, debentures (the "Debentures") in the aggregate principal amount of $11,000,000 (the "Subscription Amount") in *two* tranches with the purchase price of the Debentures in each tranche being equal to 96% of the Subscription Amount to be purchased. The closing of the initial tranche of Debentures occurred on *March 6, 2026 (*the "First Closing"), in which the Company issued Debentures in the aggregate principal amount of $4,000,000 (the "First Closing Debentures") to the Investor. Pursuant to the SPA, the Company and the Investor have agreed that the closing of the *second* tranche of the remaining $7,000,000 in aggregate principal amount of the Debentures (the "Second Closing" and such Debentures, the "Second Closing Debentures") will occur on or before the *first* business day after the Company's filing of the registration statement with Securities and Exchange Commission registering the resale of the shares of the Company's common stock issuable upon exercise of the Warrants (as defined below) and *no* less than 10,000,000 shares of the Company's common stock issuable pursuant to the A&R SEPA (such registration statement, the "Resale Registration Statement"), has been declared effective and subject to the satisfaction or waiver of customary closing conditions set forth in the SPA. The sale of the Debentures to the Investor is expected to result in gross proceeds to us of approximately $10.5 million, after deducting a *one*-time due diligence and structuring fee to the Investor of $25,000 but before deducting any other fees and expenses.

In addition, in connection with the First Closing, as a commitment fee for the transactions contemplated by the SPA, the Company issued to the Investor warrants to purchase up to 1,291,778 shares of the Company's common stock at an exercise price of $0.01 per share (the "Warrants"). The Warrants are immediately exercisable and will expire *60* months from the date of issuance. The Warrants include customary adjustment provisions for stock splits, combinations and similar events.

The Debentures bear interest at a rate of 5.0% per annum, subject to a potential increase to 18.0% per annum upon the occurrence of certain events of default. The Debentures mature on *March 6, 2027 (*the "Maturity Date"). The Company will repay the outstanding principal of the Debentures in monthly installments of (i) $363,636 for the First Closing Debentures and (ii) $636,364 for the Second Closing Debentures, in each case, plus accrued and unpaid interest, in cash, beginning on the *30th* calendar day following the effectiveness of the Resale Registration Statement, with all remaining outstanding principal plus accrued and unpaid interest due in full on the Maturity Date. Any outstanding principal amount of, and accrued and unpaid interest on, the Debentures as of the Maturity Date will be due and payable on the Maturity Date.

The Debentures provide the Company with an optional redemption right pursuant to which we, at any time, *may* redeem in cash, in whole or in part, all amounts outstanding under the Debentures prior to the Maturity Date. The redemption amount shall be equal to the outstanding principal balance of the Debentures being redeemed by the Company, plus all accrued and unpaid interest thereon as of such redemption date.

Net proceeds of $3,815,000 received in the First Closing were allocated to the Debentures and Warrants based on their relative fair values on the First Closing. The Debentures are classified as Short-term Notes Payable and the Warrants are classified as Additional Paid-in-Capital on the Company's unaudited condensed consolidated balance sheets. The Company elected the fair value option for the Debentures and as a result, recorded an unrealized loss of $108,800 for the *three* months ended *March 31, 2026* on the Company's unaudited condensed consolidated income statements.

The following table depicts the future annual minimum payments of the Company's outstanding debt as of *March 31, 2026:*

---

| | |
|:---|:---|
|  | ***Amount*** |
| **Remainder of 2026** | $**3448780** |
| **2027** | **1090908** |
| **Total Payments** | $**4539688** |

---

***5.*** **Stockholders' Equity**

The Company has 5,000,000 authorized shares of its preferred stock, par value $0.00001 per share, on *March 31, 2026* and *December 31, 2025.* There was no outstanding shares of preferred stock on *March 31, 2026* and *December 31, 2025.*

The Company has 350,000,000 authorized shares of its common stock, par value $0.00001 per share, of which 12,930,719 and 7,736,129 shares of the Company's common stock were outstanding on *March 31, 2026* and *December 31, 2025,* respectively.

*A&R SEPA*

On *September 23, 2024,* the Company entered into the Original SEPA, which was amended and restated pursuant to the A&R SEPA on *October 31, 2024.* Pursuant to the A&R SEPA, except for so long as there is a balance outstanding under the Promissory Notes and the Additional Promissory Notes and subject to certain limitations and conditions set forth therein, the Company has the right, but *not* the obligation, to sell to the Investor, and the Investor agreed to purchase from the Company, an aggregate amount of up to $25,000,000 of shares of the Company's common stock at the Company's request, from time to time, until *November 1, 2027.* See Note *4* – Debt.

***6.*** **Stock Warrants**

The Company's outstanding warrants as of *March 31, 2026* are summarized as follows, and all were exercisable at that date.

---

| | | | |
|:---|:---|:---|:---|
|  | ***Number of Shares*** | ***Exercise Price*** | ***Remaining Contractual Life (years)*** |
| Outstanding warrants expiring May 7, 2026 | 95834 | $200.00 | 0.10 |
| Outstanding warrants expiring September 11, 2026 | 51205 | $16.60 | 0.46 |
| Outstanding warrants expiring March 6, 2031 | 1291778 | $0.01 | 4.92 |
| Outstanding warrants at March 31, 2026 | 1438817 |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *10*

------

 *December 2020* Warrants*

The warrants issued pursuant to a securities purchase agreement, dated as of *December 24, 2020,* that the Company entered into with certain institutional and accredited investors and pursuant to which, among other things, the Company sold and issued, and the investors purchased, shares of the Company's common stock and related warrants to purchase additional shares of the Company's common stock in a series of *two* closings, contain a call provision whereby the Company, after the *13*-month anniversary of the issuance date, and if the volume weighted average price of the common stock for such date exceeds *four* times the exercise price of the warrants for *20* consecutive trading days, *may* call the warrants that have *not* previously been exercised, and the warrant holders have *ten* trading days within which to exercise before the warrants *may* be cancelled. From among these warrants, warrants for 1,283 shares of common stock expired in *2023,* warrants for 43,125 shares of common stock expired on *January 28, 2025,* and warrants for 95,834 shares of common stock will expire on *May 7, 2026.*

 *September 2024* Warrants*

On *September 12, 2024,* the Company entered into securities purchase agreements with *four* private investors with respect to the private placement of an aggregate of 51,205 shares of the Company's common stock at a price of $16.60 per share and warrants to purchase up to an aggregate of 51,205 shares of the Company's common stock. The Company received aggregate gross cash proceeds from this private placement (exclusive of proceeds from any future exercise of the warrants) of $850,000. The warrants have a term of two years and are exercisable at any time after *September 16, 2024,* at an exercise price of $16.60 per share. The warrants expire on *September 11, 2026.*

 *March 2026* Warrants*

As disclosed in Note *4* - Debt, the Company issued to the Investor Warrants to purchase up to 1,291,778 shares of the Company's common stock at an exercise price of $0.01 per share in conjunction with the issuance of the Debentures. The Warrants are immediately exercisable and will expire *60* months from the date of issuance. The Warrants include customary adjustment provisions for stock splits, combinations and similar events.

***7.*** **Stock Options and Restricted Shares**

The outstanding options at *March 31, 2026* consisted of the following:

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | ***Weighted*** |
|  |  |  | ***Average*** |
|  |  |  | ***Remaining*** |
|  | ***Number of*** | ***Exercise*** | ***Contractual Life*** |
|  | ***Shares*** | ***Price*** | ***(years)*** |
| Outstanding at December 31, 2025 | 977250 |  |  |
| Options Expired at $22.00 Exercise Price | (1000) | $22.00 |  |
| Options Expired at $15.00 Exercise Price | (80000) | $15.00 |  |
| Options forfeited at $22.00 Exercise Price | (1000) | $22.00 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Outstanding at March 31, 2026 | 895250 |  |  |
| Outstanding Options at $20.00 Exercise Price | 25000 | $20.00 | 5.77 |
| Outstanding Options at $24.00 Exercise Price | 9090 | $24.00 | 5.77 |
| Outstanding Options at $90.00 Exercise Price | 25675 | $90.00 | 4.73 |
| Outstanding Options at $262.00 Exercise Price | 675 | $262.00 | 2.30 |
| Outstanding Options at $21.00 Exercise Price | 58850 | $21.00 | 7.28 |
| Outstanding Options at $21.10 Exercise Price | 136460 | $21.10 | 7.97 |
| Outstanding Options at $26.60 Exercise Price | 2500 | $26.60 | 7.87 |
| Outstanding Options at $27.50 Exercise Price | 200000 | $27.50 | 0.85 |
| Outstanding Option at $17.60 Exercise Price | 10000 | $17.60 | 8.22 |
| Outstanding Options at $14.90 Exercise Price | 2000 | $14.90 | 8.18 |
| Outstanding Options at $2.50 Exercise Price | 415000 | $2.50 | 8.95 |
| Outstanding Options at $2.12 Exercise Price | 10000 | $2.12 | 9.14 |
| Outstanding at March 31, 2026 | 895250 |  |  |

---

As of *March 31, 2026*, 689,485 of the outstanding stock options were exercisable. Unrecognized compensation for unvested shares was $70,931 as of *March 31, 2026.*

As of *March 31, 2026*, the outstanding stock options had intrinsic value of $0.

*Performance Options*

On *February 28, 2024,* the Company issued options to an external party to purchase 200,000 shares of the Company's common stock at an exercise price of $27.50 per share, contingent upon achieving certain sales targets. On *March 31, 2026,* the sales targets were *not* met and therefore, *no* compensation expense was recorded for the *three* months ended *March 31, 2026.* The Company does *not* believe that the criteria will be met. These options expire on *February 5, 2027.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *11*

------

***8.*** **Related Party Transactions**

The Company has entered into lease agreements with SRI Professional Services, Incorporated ("SRI"), pursuant to which the Company leases equipment used in connection with the operation of its business (the "SRI Equipment Leases"). Phillip W. Oldridge, the Company's Chief Executive Officer and Chairman of the Board, serves as an executive officer and a member of the board of directors of SRI. Two of the SRI Equipment Leases provide for the leasing of *two* vehicles that commenced on *January 1, 2020* and the combined rent under such leases is $3,880 per month, and a *third* SRI Equipment Lease provides for a trailer lease that commenced on *December 1, 2019,* under which the rent is $3,891 per month. The total monthly payment obligation of the Company under the SRI Equipment Leases is $7,771. As a result of the SRI Equipment Leases, the Company recorded rent expense of $23,312 and $23,312 for the *three* months ended *March 31, 2026* and *2025,* respectively.

The Company has entered into a commercial lease agreement (the "ABCI Office Lease") with Alpha Bravo Charlie, Inc. ("ABCI") that commenced on *April 1, 2020,* for the lease of office space in Porterville, California. The monthly rent for this facility is approximately $5,000. Phillip W. Oldridge, the Company's Chief Executive Officer and Chairman of the Board, is a director of ABCI. The Company recorded rent expense of $15,000 and $15,000 for the *three* months ended *March 31, 2026* and *2025,* respectively, in connection with the ABCI Office Lease.

The Company also expensed $131,000 and $15,000 for the *three* months ended *March 31, 2026* and *2025,* respectively, to Shell Castle LLC, an entity owned by Jason Maddox for services rendered as President and Interim Chief Financial Officer of the Company in lieu of wages. In addition, the Company also expensed $131,000 and $15,000 for the *three* months ended *March 31, 2026* and *2025,* respectively, to Met Consulting LLC, an entity owned by Elgin Tracy for services rendered as Chief Operating Officer of the Company in lieu of wages.

All revenue earned for the *three* months ended *March 31, 2026* and *2025* by the Company's medical supplies segment was from Maddox Medical Corp. ("Maddox Medical"), a company owned by Jason Maddox, President and Interim Chief Financial Officer of the Company, through a contract that Maddox Medical holds with a *third* party (that supplies medical gowns, among other things, to the federal government) that is fulfilled by Maddox Industries, a wholly-owned subsidiary of the Company.

The Company also maintains a procurement contract for electric vehicles and their components and accessories with EVTV Canada, a related party whereby *one* of its officers holds a significant number of shares in the Company.

On *April 1, 2025,* the Company entered into a *three*-year sub-lease arrangement with Maddox Defense (with renewal options), an entity of which Jason Maddox, the President and Interim Chief Financial Officer of the Company, is the sole stockholder, to lease a facility in Houston, Texas for its corporate and administrative operations. See Note *10* - Leases for additional disclosures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *12*

------

***9.*** **Commitments and Contingencies**

*Commitments*

See Note *10* - Leases for further information.

*Contingencies*

Except as set forth below, we know of *no* material, existing or pending, legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are *no* proceedings in which any of our directors, officers or affiliates, or any registered or beneficial stockholder of more than *5%* of our common stock, or any associate of any of the foregoing persons, is an adverse party or has a material interest adverse to our interest.

*GreenPower Litigation*

The Company is named as a defendant in litigation commenced in the Supreme Court of British Columbia, Canada, originally filed on *December 17, 2019* by GreenPower Motor Company Inc. ("GreenPower"), along with certain related entities and individuals, including an executive officer of the Company. The claims generally allege, among other things, breach of fiduciary duty, misuse of confidential information, unfair competition, and related matters. The Company and the other named defendants have denied these allegations. In addition, certain of the defendants, including the Company, are named in a related counterclaim proceeding.

The litigation was previously scheduled for trial in *2024;* however, the trial was adjourned by consent of the parties. As of *December 31, 2025, no* new trial date has been set, limited discovery has been conducted, and there has been *no* material activity in the proceedings during fiscal year *2025.* The matter remains in an early procedural stage.

*Lawsuit against Efraim Diveroli and Kingbird Ventures LLC*

On *February 5, 2026,* the Company sued Efraim Diveroli and Kingbird Ventures LLC in the Houston Division of the Texas Business Court, alleging that the defendants, acting individually and in concert with *one* another, caused agents and representatives of theirs, including Joel E. Tasca of Greenberg Traurig, to spread lies about the Company, its principals, and its business partners in an effort to scuttle the expected merger with Azio AI Corporation. The Company asserted claims for tortious interference with contract, tortious interference with prospective economic advantage, and defamation and business disparagement as well as seeking emergency and temporary injunctive relief. On *February 9, 2026,* Kingbird Ventures removed the case to the United States District Court for the Southern District of Texas. An initial pretrial and scheduling conference is set on *May 28, 2026. No* scheduling order has been entered, nor has a trial date been set. While the Company believes that its claims have merit, even if there is an unfavorable outcome, the Company does *not* expect to be subjected to a material loss.

*Lawsuit against Efraim Diveroli, Kingbird Ventures LLC, VD Acquisitions, LLC, Bront Bird, and Karla Mae Capital, LLC*

On *December 8, 2025,* the Company and Maddox Defense, Inc. ("Maddox Defense"), an entity wholly owned by Jason Maddox, the Company's President and Interim Chief Financial Officer, sued Efraim Diveroli, Kingbird Ventures LLC, VD Acquisitions, LLC, Bront Bird, and Karla Mae Capital, LLC in the Southern District of California, alleging that defendants, acting individually and in concert with *one* another, engaged in coercive and extortionate activities, including through abuse of the legal process, in an attempt to force the Company into unwanted transactions, including with Fenix Oro, a gold-mining enterprise. The Company asserted claims for civil extortion; RICO, *18* U.S.C. § *1962*(c); fraudulent inducement; tortious interference with contract; tortious interference with prospective economic relations; abuse of process; declaratory relief; injunctive relief; civil conspiracy; and unfair competition, Bus. & Prof. Code § *17200.* On *January 7, 2026,* the claims against Bront Bird and Karla Mae Capital were voluntarily dismissed with prejudice. *No* responsive pleadings have been filed. *No* scheduling order has been entered, nor has a trial date been set. While the Company believes that its claims have merit, even if there is an unfavorable outcome, the Company does *not* expect to be subjected to a material loss.

*Lawsuit from VD Acquisitions*

On *January 14, 2026,* VD Acquisitions LLC filed suit against Jason Maddox, Elgin Tracy, Maddox Defense; Maddox Industries, a wholly-owned subsidiary of the Company, the Company, Phillip Oldridge, Karla Mae Capital, LLC and Airboss Defense Group, LLC, alleging that Maddox Defense had failed to perform under a fuel agreement. Plaintiff asserted claims for breach of contract, fraud in the inducement; fraudulent transfer; civil conspiracy; intentional interference with contract; and declaration of alter ego. The plaintiff seeks monetary damages and injunctive relief restraining the assets of Jason Maddox, Maddox Defense, Maddox Industries, and the Company. On *February 10, 2026,* the Court held a hearing on the plaintiff's motion for a temporary restraining order and denied the requested relief. The Company disputed these allegations and vigorously defended itself. The Company was successful and the VD Acquisitions withdrew its case in the Delaware Courts in *April 2026.*

*Litigation with Former Independent Auditor*

In *December 2025,* the Company initiated legal proceedings against its former independent registered public accounting firm, MaloneBailey LLP ("MaloneBailey"), in the United States District Court for the Central District of California (Case *No. 5:25*-cv-*03457*). The complaint alleges, among other things, breach of contract and related claims arising from MaloneBailey's engagement to audit the Company's financial statements for the fiscal year ended *December 31, 2022.* Specifically, the Company asserts that MaloneBailey failed to complete required audit procedures and did *not* issue an audit report in connection with the Company's Annual Report on Form *10*-K for the *2022* fiscal year, despite having been engaged to do so.

MaloneBailey previously served as the Company's independent auditor. During *2023,* the Company disclosed that MaloneBailey would *not* provide an audit opinion on the Company's financial statements for the fiscal year ended *December 31, 2022.* As a result, the Company engaged a successor independent registered public accounting firm to complete the audit and support its financial reporting obligations.

The Company's claims are based on alleged contractual breaches and professional failures related to MaloneBailey's audit engagement. The Company is seeking damages and other relief deemed appropriate by the court. As of *March 31, 2026,* the litigation is in its early stages. The complaint was recently filed, and *no* substantive rulings have been issued by the court. The Company cannot predict the timing or outcome of this matter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *13*

------

***10.*** **Leases**

*Operating leases*

The Company has active operating lease arrangements for office space and warehouse facilities. The Company is typically required to make fixed minimum rent payments relating to its right to use the underlying leased assets. Although these leases have terms that are either month-to-month or terms that are *one* year or less (with renewal options), the Company concluded that the term renewal options are reasonably certain to be exercised, and the Company classified such leases as operating leases in accordance with the provisions of ASC *842.*

On *March 1, 2026,* the Company entered into a one-year lease arrangement with TexOil Ventures LLC ("TexOil") (with one-year renewal options) for pilot infrastructure and computing operations. This lease is treated as an operating lease in accordance with the provisions of ASC *842.* Therefore, the Company recognized operating lease liabilities with corresponding ROU assets based on the present value of the minimum rental payments of such leases. The Company paid a nonrefundable deposit of $390,000 and will make monthly payments of $38,500 to TexOil. The Company granted TexOil a *first*-priority security interest in all computing and mining equipment located at the leased site. Upon default by the Company and expiration of the applicable cure period, TexOil *may* foreclose and take title to such equipment under the Texas Uniform Commercial Code.

On *April 1, 2025,* the Company entered into a three-year sub-lease arrangement with Maddox Defense (with renewal options), an entity of which Jason Maddox, the President and Interim Chief Financial Officer of the Company, is the sole stockholder, to lease a facility in Houston, Texas for its corporate and administrative operations. This lease is treated as an operating lease in accordance with the provisions of ASC *842.* Therefore, the Company recognized operating lease liabilities with corresponding ROU assets based on the present value of the minimum rental payments of such leases.

On *July 1, 2024,* the Company entered into a month-to-month lease contract to lease a residence in Osceola, Arkansas for the purpose of housing certain of the Company's employees. The monthly lease cost is $3,000. This lease is treated as a short-term lease.

On *August 26, 2024,* the Company entered into a *one*-year lease contract to lease a location in Manalapan, New Jersey with the purpose of servicing the Company's New Jersey customers. The monthly lease cost is $2,900 and at the end of the *one*-year lease term, the lease converted into a month-to-month arrangement. This lease is treated as a short-term lease.

The Company's lease agreements do *not* provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an appropriate incremental borrowing rate. The Company benchmarked itself against other companies of similar credit ratings and comparable credit quality and derived an incremental borrowing rate to discount each of its lease liabilities based on the remaining lease terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *14*

------

Quantitative information regarding the Company's leases is as follows:

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** |
|  | ***March 31,*** | ***March 31,*** |
|  | ***2026*** | ***2025*** |
| ***Lease expenses*** |  |  |
| Operating lease expenses | $72384 | $38312 |
| Short-term lease expenses | 69100 | 46826 |
| Total lease cost | $141484 | $85138 |
| ***Other information*** |  |  |
| Cash paid for the amounts included in the measurement of lease liabilities for operating leases: |  |  |
| Operating cash flows | $59091 | $38312 |
| Weighted-average remaining lease term (in years): |  |  |
| Operating leases | 2.71 | 0.50 |
| Weighted-average discount rate: |  |  |
| Operating leases | 14% | 14% |

---

Future minimum payments under operating leases are as follows:

---

| | |
|:---|:---|
| **Remainder of 2026** | $**530863** |
| **2027** | **715192** |
| **2028** | **547217** |
| **2029** | **115500** |
| **Total payments** | $**1908772** |

---

***11.*** **Segment Reporting**

The Chief Operating Decision Maker is the Chief Executive Officer, who reviews the segment operating results in order to allocate resources and assess performance.

The Company has identified four segments:

(*1*) Electric vehicles,

(*2*) Medical supplies,

(*3*) Artificial Intelligence ("AI") Infrastructure, and

(*4*) Drones.

The electric vehicle segment consists of sales of commercial electric vehicles to customers. A significant portion of such sales are through state subsidized or funded programs. The medical supplies segment consists solely of sales to Maddox Defense, a related party based on an agreement to supply refurbished medical gowns on a cost-plus pricing arrangement. Through the Company's drone operations, it is also diversifying its portfolio of assets by engaging in the future production and supply of drones that will be used in the agricultural environment as well as engaging in AI activities. Currently, activity within the drones segment is limited to start up expenses and research and development activities. AI expenses are primarily lease expenses.

The table below summarizes the operating results of the Company's segments for the *three* months ended *March 31, 2026* and *March 31, 2025:* 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | ***Three months ended March 31, 2026*** | ***Three months ended March 31, 2026*** | ***Three months ended March 31, 2026*** | ***Three months ended March 31, 2026*** | ***Three months ended March 31, 2026*** | ***Three months ended March 31, 2026*** |
|  | ***Electric vehicles*** | ***Medical Supplies*** | ***AI Data Infrastructure*** | ***Drones*** | ***Corporate*** | ***Total*** |
| Sales, net | $- | $2248621 | $- | $- | $- | $2248621 |
| Operating Income (Loss) | $(221496) | $(44989) | $(49333) | $(10000) | $(3445231) | $(3771049) |
| Interest income (expense), net |  |  |  |  |  | 50 |
| Loss on conversion and changes in fair value of convertible notes |  |  |  |  |  | (106997) |
| Other expense |  |  |  |  |  | (108927) |
| Income tax expense |  |  |  |  |  |  |
| Net loss |  |  |  |  |  | $(3986923) |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | ***Three months ended March 31, 2025*** | ***Three months ended March 31, 2025*** | ***Three months ended March 31, 2025*** | ***Three months ended March 31, 2025*** | ***Three months ended March 31, 2025*** | ***Three months ended March 31, 2025*** |
|  | ***Electric vehicles*** | ***Medical Supplies*** | ***AI Data Infrastructure*** | ***Drones*** | ***Corporate*** | ***Total*** |
| Sales, net | $373300 | $217267 | $- | $- | $- | $590567 |
| Operating loss | $(10098294) | $(745934) | $- | $(93027) | $(2794418) | $(13731673) |
| Interest income (expense), net |  |  |  |  |  | 10754 |
| Loss on conversion and changes in fair value of convertible notes |  |  |  |  |  | (283793) |
| Other expense |  |  |  |  |  | (31669) |
| Income tax expense |  |  |  |  |  |  |
| Net loss |  |  |  |  |  | $(14036381) |

---

***12.*** **Subsequent Events**

The Company evaluates subsequent events that have occurred after the balance sheet date but before the unaudited condensed consolidated financial statements are issued. There are *two* types of subsequent events: (*1*) recognized, or those that provide additional evidence with respect to conditions that existed at the date of the balance sheet, including the estimates inherent in the process of preparing financial statements, and (*2*) non-recognized, or those that provide evidence with respect to conditions that did *not* exist at the date of the balance sheet but arose subsequent to that date.

In *May 2026,* the Company received net proceeds of approximately $5,850,000 from the issuance of the *second* tranche of the debenture disclosed in Note *4* - Debt. Approximately $2,560,000 of these proceeds were used to purchase certain equipment that will be used in the operations of the Company's AI Data Infrastructure segment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *15*

------

**ITEM 2. MANAGEMENT**'**S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following discussion of our financial condition and the results of operations should be read in conjunction with the unaudited consolidated financial statements and notes thereto included in this Quarterly Report and the audited financial statements and notes thereto included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on April 13, 2026. This discussion contains forward-looking statements that are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements. These risks, uncertainties, and other factors include, among others, those identified under the "Special Note Regarding Forward-Looking Statements" above in this Quarterly Report.

**Overview**

We are a United States distributor of zero-emission commercial vehicles and heavy capacity drones engineered for logistics, infrastructure, and precision agriculture applications worldwide. Our systems enable a cleaner, safer, and more efficient future for critical industrial operations. We operate under four segments: electric vehicles, medical supplies, AI data infrastructure and drones.

For the three months ended March 31, 2026 and 2025, we generated sales revenue of $2,248,621 and $590,567 respectively, and our net loss for the three months ended March 31, 2026 and 2025 was $3,986,923 and $14,036,381, respectively. Included in our net loss for the three months ended March 31, 2026 is a loss on conversion and changes in fair value of convertible notes of $108,800. Included in our net loss for the three months ended March 31, 2025 is a loss on conversion and changes in fair value of convertible notes of $283,793 and a non-cash impairment charge of $10,103,048 for goodwill.

&nbsp;&nbsp;&nbsp;&nbsp; *One Big, Beautiful Bill Act (the "Act")*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The demand for our vehicles may be affected adversely by the Act due to significant reductions in electric vehicle credits made available to consumers. This may affect our future profitability.

&nbsp;&nbsp;&nbsp;&nbsp; *Import Tariffs*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tariffs imposed by the Presidential administration may significantly affect demand for our vehicles or reduce our gross profits if we are unable to pass such tariffs to our customers. We are currently assessing the impact and will take appropriate action to minimize the impact of such tariffs on our electric vehicle strategy.

&nbsp;&nbsp;&nbsp;&nbsp; **Nasdaq Deficiency Notice**

On April 29, 2026, we received a notice (the "Notice") from the Listing Qualifications Department of Nasdaq notifying us that, because our stockholders' equity was below $2,500,000 as reported on the Company's Annual Report on Form 10-K for the year ended December 31, 2025, we no longer meet the minimum shareholders' equity requirement of $2,500,000 for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(1).

**Going Concern and Management**'**s Plan**

Our unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. We sustained significant losses and negative cash flows from operations and are dependent on the overall improvement of our operating activities as well as debt and equity financing to fund operations. We incurred a net loss of $3,986,923 and $14,036,381 for the three months ended March 31, 2026 and 2025, respectively. Cash used in operating activities was $3,342,098 and $4,217,480 for the three months ended March 31, 2026 and 2025, respectively. Accumulated deficit was $116,575,383 and $112,588,460 as of March 31, 2026 and December 31, 2025, respectively.

As a result of these conditions, substantial doubt exists about our ability to continue as a going concern within one year after the filing of this Quarterly Report. The unaudited condensed consolidated financial statements included elsewhere herein do not include any adjustments that might be necessary if we were unable to continue as a going concern.

As more fully described above under "Debenture Financing," we closed the initial tranche of Debentures in the First Closing on March 6, 2026, resulting in net proceeds of approximately $3.8 million. We also closed the second tranche of Debentures in the second closing on May 7, 2026, resulting in net proceeds of approximately $5.8 million. We also plan to grow and expand our operations and seek additional sources of capital through either an additional debt or equity financial and to pursue acquisitions of cash flow generating assets or businesses. Although we have been successful in raising funds in the past, and expect to do so in the future, there are no guarantees that we will be able to raise funds as anticipated. In addition, there is no assurance that any such acquisition will be successful or that we will realize the anticipated benefits for such acquisition following the closing.

**Factors Affecting Our Performance**

We believe that the growth and future success of our business depend on various opportunities, challenges and other factors, including the following:

***Availability of government subsidies, rebates and economic incentives.*** We believe that the availability of government subsidies, rebates, and economic ****incentives is currently a critical factor considered by our customers when purchasing our zero-emission systems or converting their existing vehicles to zero-emission-electric or hybrids, and that our growth depends in large part on the availability and amounts of these subsidies and economic incentives. As an alternative to being dependent on such funding, however, we are exploring the possibility of leasing our vehicles to our customers as well.

***New customers.*** We are competing with other companies and technologies to help fleet managers and their districts/companies more efficiently and ****cost-effectively manage their fleet operations. Once these fleet managers have decided they want to buy from us, we still face challenges with helping them to obtain financing options to reduce the cost barriers to purchasing. We may also encounter customers with inadequate electrical services at their facilities that may delay their ability to purchase from us.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16

------

***Dependence on external sources of financing of our operations.*** We have historically depended on external sources of capital to finance our ****operations. Accordingly, our future performance will depend in part upon our ability to achieve independence from external sources for the financing of our operations.

***Investment in growth.*** We plan to continue to invest for long-term growth. We anticipate that our operating expenses will increase in the foreseeable ****future as we invest in research and development to enhance our zero-emission electric vehicles and systems; design, develop and manufacture our commercial fleet vehicles and their components; increase our sales and marketing to acquire new customers; and increase our general and administrative functions to support our growing operations. We believe that these investments will contribute to our long-term growth, although they will adversely affect our results of operations in the near term. In addition, the timing of these investments can result in fluctuations in our annual and quarterly operating results.

***Zero-emission electric vehicle experience.*** Our dealer and service network is not currently completely established, although we do have certain ****agreements in place. One issue they may have, and we may encounter, is finding appropriately trained technicians with zero-emission electric fleet vehicle experience. Our performance will depend on having a robust dealer and service network, which will require appropriately trained technicians to be successful. Because vehicles that utilize our technology are based on a different technology platform than traditional internal combustion engines, individuals with sufficient training in zero-emission electric vehicles may not be available to hire, and we may need to expend significant time and expense training the employees we do hire. If we are not able to attract, assimilate, train or retain additional highly qualified personnel in the future, or do so cost-effectively, our performance would be significantly and adversely affected.

***Market growth.*** We believe the market for all-electric solutions for alternative fuel technology, specifically all-electric vehicles, will continue to grow as ****more purchases of new zero-emission vehicles and as more conversions of existing fleet vehicles to zero-emission vehicles are made. However, unless the costs to produce such vehicles decrease dramatically, purchasers of our products will continue to depend in large part on financing subsidies from government agencies. We cannot be assured of the continued availability, the amounts of such assistance to our customers, or our ability to access such funds.

***Sales revenue growth from additional products*.**We seek to add to our product offerings additional zero-emission vehicles of all sizes to be marketed, ****sold, warrantied and serviced through our developing distribution and service network, as well as add other ancillary products discussed elsewhere in this Quarterly Report.

***Third-party contractors, suppliers and manufacturers.*** We rely upon third parties to supply us with raw materials, parts, components and services in ****adequate quantity in a timely manner and at reasonable prices, quality levels, and volumes acceptable to us. We also are solely reliant on one vendor which is a related party to provide all vehicles as there is currently no manufacturing in the United States.

**Components of Results of Operations**

***Sales***

Under the vehicles segment, sales are recognized from the sales of new, purpose-built zero-emission electric vehicles and from providing vehicle maintenance and safety inspection services. Under the medical supplies segment, revenue is recognized at the point in time when control transfers to the customer, which occurs when the medical gowns are delivered to the third party. Sales are recognized in accordance with ASC 606, as discussed in Note 2 to our unaudited consolidated financial statements included in this Quarterly Report.

***Cost of Sales***

Cost of sales for our electric vehicles segment includes those costs related to the development, manufacture, and distribution of our electric vehicles. Specifically, we include in cost of sales for our electric vehicles segment each of the following: material costs (including commodity costs); freight costs; labor and other costs related to the development and manufacture of our electric vehicles; and other associated costs. Cost of sales also includes costs related to the valuation of inventory due to impairment, obsolescence, or shrinkage. Cost of sales included in our medical supplies activities include direct labor and accessories such as tape, glues, etc. The main materials of our medical supplies segment are supplied by the customer.

***General and Administrative Expenses***

Selling, general and administrative expenses include all corporate and administrative functions that support our Company, including personnel-related expense and stock-based compensation costs; costs related to investor relations activities; including product recall and customer satisfaction program costs; consulting costs; marketing-related expenses; and other expenses that cannot be included in cost of sales.

***Consulting and Research and Development Costs***

These expenses are related to our consulting and research and development activity.

***Other (Expense)Income, Net***

Other (expense)/income include non-operating income and expenses, including interest income and expense, realized gain/(loss) on conversion of convertible notes and unrealized gain (loss) of financial instruments at fair value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17

------

***Provision for Income Taxes***

We account for income taxes in accordance with ASC 740 which requires the recognition of deferred income tax assets and liabilities for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that we will not realize tax assets through future operations. Because we have incurred only losses to this point, no provision for income taxes has been made in 2025.

<u>Results of Operations</u>

The following discussion compares our results of operations for the three months ended March 31, 2026 to the corresponding period ended March 31, 2025:

***Sales***

Sales for the three months ended March 31, 2026 and 2025 were $2,248,621 and $590,567, respectively. Sales for the three months ended March 31, 2026 of our electric vehicle segment was $0. Sales of our medical supplies segment consisted of delivery of medical supplies totaling $2,248,621 to a related party. Sales for the three months ended March 31, 2025 of our electric vehicle segment were $373,130 and consisted primarily of two class 4 trucks and one cargo van. Sales of our medical supplies segment consisted of delivery of medical gowns totaling $217,437 to a related party.

***Cost of Sales***

Cost of sales for the three months ended March 31, 2026 and 2025 were $2,437,233 and $471,175, respectively. Cost of sales of our electric vehicles segment was $160,511 for the three months ended March 31, 2026 from the write-down of a portion of our U.S. Environmental Protection Agency ("EPA") fulfillment asset. Cost of sales of our medical supplies segment was $2,276,722 for the three months ended March 31, 2026. Cost of sales for our medical supplies segment was based on a cost-plus pricing structure to a related party. Cost of sales for the three months ended March 31, 2025 consisted of the costs related to the sale of the electric vehicles sold and the delivery of medical gowns as described above.

***General and Administrative ("G&A") Expenses***

G&A expenses were $3,572,437 and $3,603,108 for the three months ended March 31, 2026 and 2025, respectively. G&A expenses decreased slightly by $30,671 primarily due to lower payroll and benefits of $39,590 as a result of restructuring activities in 2025, lower contract labor of $581,747 due to lower level of activities, lower taxes and licenses of $202,573, lower commissions paid of $200,000, lower stock-based compensation of $521,067 as no awards were granted in the first quarter of 2026, lower amortization expense of $222,500 as all amortizable intangibles were written-off in the third quarter of 2025, lower overall costs of $133,937 due to cost-cutting measures taken, partially offset by higher legal and accounting costs of $1,870,743 due to an SEC investigation and additional lawsuits filed against various parties as well outside accounting consultants employed to manage the accounting activities.

***Consulting Expenses***

Consulting expenses were $0 and $46,511 for the three months ended March 31, 2026 and 2025, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18

------

***Research and Development ("R&D") Expenses***

R&D expenses were $10,000 and $98,398 for the three months ended March 31, 2026 and 2025, respectively, as the level of activity decreased.

***Goodwill Impairment Charge***

Due to our declining stock price, we conducted an impairment test related to our goodwill in the first quarter of 2025. As a result of this test, we recorded an impairment charge of $10,103,048 related to our goodwill for the three months ended March 31, 2025.

***Loss on conversion and changes in fair value of convertible notes***

We recorded a non-cash loss on conversion and changes in fair value of convertible notes of $106,997 for the three months ended March 31, 2026 and $283,793 for the three months ended March 31, 2025, on our financial instruments that we elected to measure at fair value.

<u>Cash Flows</u>

The following table summarizes our cash flows from operating, investing, and financing activities for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **Three months ended March 31,** | **Three months ended March 31,** |
|  | **2026** | **2025** |
| Cash flows used in operating activities | $(3342098) | $(4217480) |
| Cash flows used in investing activities | (1525900) | (176828) |
| Cash flows provided by financing activities | 6522849 | 2664411 |
| Net change in cash, restricted cash and cash equivalents | $1654851 | $(1729897) |

---

*Operating Activities* 

Net cash used in operating activities for the three months ended March 31, 2026 was $3,342,098, primarily due to a net loss of $3,986,923, partially offset by changes in operating assets and liabilities, net of $448,283 and non-cash operating charges of $196,542. The changes in operating assets and liabilities, net were due to a decrease in EPA fulfillment asset of $160,511, an increase in accounts payable for $1,341,248 and an increase in accrued liabilities of $68,986, partially offset by an increase of $364,595 in other current assets, an increase in prepaid expenses of $112,654, and an increase in other non-current and right-of-use assets of $334,376, a decrease in EPA contract liability of $23,625, and a decrease in other liabilities of $42,330.

Net cash used in operating activities for the three months ended March 31, 2025 was $4,217,480, primarily due to a net loss of $14,036,381 and changes in operating assets and liabilities, net of $1,395,200, partially offset by non-cash operating charges of $11,214,101. The changes in operating assets and liabilities, net was due to an increase in receivable from related party of $202,663, and increase in miscellaneous receivable of $2,249,515 (related to certain fraudulent activities related to our banking operations and that was subsequently credited back to us), and increase in inventory deposits of $2,675,003 (primarily from deposits for our EPA grant program) and a decrease in other liabilities of $30,467, partially offset by a decrease in accounts receivable of $164,541, a decrease in inventory of $167,108, a decrease in prepaid expenses of $629,596, a decrease in other current and non-current assets of $55,751, an increase in accounts payable and accrued liabilities of $461,037 and an increase in deferred revenue of $2,284,415 (primarily related to our EPA grant program).

We expect cash used in operating activities to fluctuate significantly in future periods as a result of a number of factors, some of which are outside of our control, including, among others: the success we achieve in generating revenue; the success we have in helping our customers obtain financing and government incentives to subsidize their purchases of our products; our ability to efficiently develop our dealer and service network; the costs of batteries and other materials utilized to make our products; the extent to which we need to invest additional funds in research and development; the amount of expenses we incur to satisfy future warranty claims, and the ability to engage in providing medical supplies to the federal government on a long-term basis.

*Investing Activities*

Net cash used in investing activities during the three months ended March 31, 2026 was $1,525,900, primarily from the purchase of property and equipment used in our current operations.

Net cash used in investing activities during the three months ended March 31, 2025 was $176,828, primarily from the purchase of property and equipment used in our current operations.

*Financing Activities*

Net cash provided by financing activities during the three months ended March 31, 2026 was $6,522,849 primarily from proceeds from the issuance of issuance of common stock for $2,677,090, issuance of our Debentures (as defined below) for $3,815,000 and issuance of other debt for $109,061, partially offset by the repayment of other debt of $78,302.

Net cash provided by financing activities during the three months ended March 31, 2025 was $2,664,411, primarily due to proceeds from the issuance of our convertible notes of $2,850,500, partially offset by the repayment of other debt of $186,089.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19

------

**Liquidity and Capital Resources**

As of March 31, 2026, we had cash and cash equivalents of $2,013,817 and negative working capital of approximately $11,538,147. To date, we have financed our operations primarily through capital raises from issuing common stock. We believe that our existing cash and cash equivalents may not be sufficient to allow us to operate for the next 12 months due to our current and potential liabilities. We may need to raise additional capital through equity or debt issuances. If we are unable to raise additional capital, we may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations and reducing overhead expenses. We cannot provide any assurance that any new financing will be available on commercially acceptable terms, if at all, or will be completed on a timely basis. These conditions raise substantial doubt about our ability to continue as a going concern.

The accompanying unaudited condensed consolidated financial statements were prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if we were unable to continue as a going concern.

In February 2022, we moved into an approximately 580,000 square foot facility in Osceola, Arkansas. We plan to close this facility in 2026.

On February 12, 2025, we announced the relocation of our corporate headquarters and the establishment of a new 86,000 square foot facility in Houston, Texas. We opened our new corporate headquarters and manufacturing facility in 2025. As a result of this relocation, we incurred additional capital expenditure and one-time relocation costs.

***Amended and Restated Standby Equity Purchase Agreement***

On October 31, 2024, we entered into the Amended and Restated Standby Equity Purchase Agreement (the "A&R SEPA") with YA II PN, Ltd. (the "Investor"). The A&R SEPA amends and restates in its entirety the standby equity purchase agreement, dated September 23, 2024, by and between the Company and the Investor (the "Original SEPA").

Pursuant to the A&R SEPA, except for so long as there is a balance outstanding under the Promissory Notes (as defined below) and the Additional Promissory Notes (as defined below), we have the right, from time to time, until November 1, 2027, to require the Investor to purchase up to $25 million of shares of our common stock, subject to certain limitations and conditions set forth in the A&R SEPA, by delivering written notice to the Investor. Pursuant to the A&R SEPA, the Investor advanced to us the principal amount of $3 million (the "Pre-Paid Advance") in exchange for our issuance to the Investor of convertible promissory notes (the "Promissory Notes") in two tranches, resulting in net proceeds (net of discounts and fees) to us of $2,635,500. We received the first tranche of the Pre-Paid Advance in the principal amount of $2 million on October 31, 2024 in exchange for the Promissory Note dated October 31, 2024 (the "EVTV-1 Promissory Note"), and the second tranche of the Pre-Paid Advance in the principal amount of $1 million on December 17, 2024 in exchange for the Promissory Note dated December 17, 2024 (the "EVTV-2 Promissory Note"). The Promissory Notes accrued interest on the outstanding principal balance at an annual rate equal to 0%, which would increase to an annual rate of 18% upon the occurrence of an Event of Default (as defined in the Promissory Notes) or a Registration Event (as defined in the Promissory Notes) for so long as such event of default remained uncured. Prior to our entry into the Supplemental Agreement (as defined below), the Promissory Notes were initially set to mature on November 13, 2025 and were convertible at a conversion price equal to the lower of (i) $21.48 per share or (ii) 93% of the lowest daily volume weighted average price of our common stock on Nasdaq Stock Market LLC ("Nasdaq") as reported by Bloomberg L.P. ("VWAP") during the five consecutive trading days immediately preceding the conversion date (but no lower than the "floor price" then in effect, which was $3.58 per share, subject to adjustment from time to time in accordance with the terms contained in the Promissory Notes). Pursuant to the terms of the Original SEPA, we issued 6,410 shares of common stock to the Investor as a commitment fee.

During 2025, the obligation under the EVTV-1 Promissory Note was partially satisfied through the conversion of the EVTV-1 Promissory Note into shares of our common stock. As a result of this conversion, 1,416,116 shares of our common stock were issued at a weighted average price of $1.06. The remaining principal balance of the EVTV-1 Promissory Note at December 31, 2025, was $285,000. The remaining obligation was fully satisfied through the conversion of the EVTV-1 Promissory Note into shares of our common stock during the first quarter of 2026. As a result of this conversion, 529,096 shares of our common stock were issued at a weighted average price of $0.63.

We have elected to measure the Promissory Notes at fair value. In estimating the fair value of the Promissory Notes, a lattice model is applied. The required inputs include the current stock price, the term, the conversion price, the risk-free rate and volatility of the common stock. The Promissory Notes' fair values are classified as Level 3 under the fair value hierarchy as provided by ASC 820.

***Supplemental Agreement to A&R SEPA***

On February 24, 2025, we entered into a supplemental agreement, dated February 24, 2025 (the "Supplemental Agreement"), with the Investor, which amends and supplements the A&R SEPA to: (i) provide for the advancement by the Investor to us, subject to the satisfaction of certain conditions as set forth in the Supplemental Agreement, of $5 million under the A&R SEPA (the "Additional Pre-Paid Advance"), to be evidenced by convertible promissory notes (the "Additional Promissory Notes") in two tranches, (ii) amend the maturity date for the EVTV-1 Promissory Note to March 9, 2026, and (iii) amend the floor price for the EVTV-1 Promissory Note to $0.7130 per share.

The Additional Promissory Notes accrued interest on the outstanding principal balance at an annual rate equal to 5%, which would increase to an annual rate of 18% upon the occurrence of an Event of Default (as defined in the Additional Promissory Notes) or a Registration Event (as defined in the Additional Promissory Notes) for so long as such event remained uncured. The Additional Promissory Notes were scheduled to mature on March 9, 2026. The Additional Promissory Notes were convertible at a conversion price equal to the lower of (i) $10.00 per share or (ii) 93% of the lowest daily VWAP during the five consecutive trading days immediately preceding the conversion date (but no lower than the "floor price" then in effect, which is $0.7130 per share, subject to adjustment from time to time in accordance with the terms contained in the Additional Promissory Notes).

The first tranche of the Additional Pre-Paid Advance was disbursed on February 25, 2025 in the principal amount of $3 million (with net proceeds to us of approximately $2.7 million after deducting discounts and fees) as evidenced by an Additional Promissory Note issued by us to the Investor on February 24, 2025 (the "EVTV-3 Additional Promissory Note"). During 2025, the obligation under the EVTV-3 Additional Promissory Note in the principal amount of $3 million was partially satisfied through the conversion of the EVTV-3 Additional Promissory Note into shares of our common stock. As a result of this conversion, 2,134,613 shares of our common stock were issued at a weighted average price of $1.51. The remaining principal balance of the EVTV-3 Additional Promissory Note on December 31, 2025, was $50,000. The remaining obligation was fully satisfied through the conversion of the EVTV-3 Additional Promissory Note into shares of our common stock during the first quarter of 2026. As a result of this conversion, 94,657 shares of the our common stock were issued at a weighted average price of $0.53.

We have elected to measure the Additional Promissory Notes at fair value. In estimating the fair value of the Additional Promissory Notes, a lattice model is applied. The required inputs include the current stock price, the term, the conversion price, the risk-free rate and volatility of our common stock. The Additional Promissory Notes' fair values are classified as Level 3 under the fair value hierarchy as provided by ASC 820.

 ***Debenture Financing***

On March 6, 2026, we entered into a securities purchase agreement (the "SPA") with the Investor, pursuant to which the Company agreed to issue and sell to the Investor, and the Investor agreed to purchase, debentures (the "Debentures") in the aggregate principal amount of $11,000,000 (the "Subscription Amount") in two tranches with the purchase price of the Debentures in each tranche being equal to 96% of the Subscription Amount to be purchased. The closing of the initial tranche of Debentures occurred on March 6, 2026 (the "First Closing"), in which we issued Debentures in the aggregate principal amount of $4,000,000 (the "First Closing Debentures") to the Investor. The closing of the second tranche of the remaining $7,000,000 in aggregate principal amount of the Debentures (the "Second Closing" and such Debentures, the "Second Closing Debentures") occurred on May 6, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In addition, in connection with the First Closing, as a commitment fee for the transactions contemplated by the SPA, we issued to the Investor warrants to purchase up to 1,291,778 shares of our common stock at an exercise price of $0.01 per share (the "Warrants"). The Warrants are immediately exercisable and will expire 60 months from the date of issuance. The Warrants include customary adjustment provisions for stock splits, combinations and similar events.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Debentures bear interest at a rate of 5.0% per annum, subject to a potential increase to 18.0% per annum upon the occurrence of certain events of default. The Debentures mature on March 6, 2027 (the "Maturity Date"). We will repay the outstanding principal of the Debentures in monthly installments of (i) $363,636 for the First Closing Debentures and (ii) $636,364 for the Second Closing Debentures, in each case, plus accrued and unpaid interest, in cash, beginning on the earlier of the 30th calendar day following

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; May 5, 2026, the date of effectiveness of our registration statement on Form S-1 to register the resale of the shares of common stock issuable upon exercise of the Warrants and additional shares of common stock issuable pursuant

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to the A&R SEPA. Any outstanding principal amount of, and accrued and unpaid interest on, the Debentures as of the Maturity Date will be due and payable on the Maturity Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Debentures provide us with an optional redemption right pursuant to which we, at any time, may redeem in cash, in whole or in part, all amounts outstanding under the Debentures prior to the Maturity Date. The redemption amount shall be equal to the outstanding principal balance of the Debentures being redeemed by us, plus all accrued and unpaid interest thereon as of such redemption date.

***Capital Expenditures***

We do not have any contractual obligations for ongoing capital expenditures at this time. We do, however, purchase equipment necessary to conduct our operations on an as needed basis and will continue increasing those expenditures as deemed necessary in our business operations.

***Contractual Obligations***

Other than as disclosed in the unaudited consolidated financial statements in Item 1 of this Quarterly Report for the period ended March 31, 2026, we have no contractual obligations.

***Critical Accounting Policies and Significant Judgments and Estimates***

Our consolidated financial statements are prepared in accordance with GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

We define our critical accounting policies as those accounting principles under GAAP that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations as well as the specific manner in which we apply those principles.

***Smaller Reporting Company Status***

We are a "smaller reporting company" as defined in Rule 12b-2 under the Exchange Act. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million measured on the last business day of our most recently completed second fiscal quarter or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million as of the last business day of our most recently completed second fiscal quarter. We may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not smaller reporting companies, including reduced disclosure about our executive compensation arrangements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20

------

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK**

We are exposed to market risks in the ordinary course of our business. We do not currently face material market risks such as interest rate fluctuation risk. Our cash and cash equivalents include cash in readily available checking and money market accounts. These investments are not dependent on interest rate fluctuations that may cause the principal amount of these investments to fluctuate, and we do not expect such fluctuation will have a material impact on our financial conditions. If we issue additional debt in the future, we will be subject to interest rate risk. The majority of our expenses are denominated in the U.S. dollar.

We may face risks associated with the costs of raw materials, primarily batteries, as we go into production. To the extent these and other risks materialize, they could have a material effect on our operating results or financial condition. We currently anticipate that our international selling, marketing and administrative costs related to foreign sales, if any, will be largely denominated in United States dollars, which may create foreign currency exchange risk exposure.

**ITEM 4. CONTROLS AND PROCEDURES**

**Limitations on Effectiveness of Controls and Procedures**

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, cannot provide absolute assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Similarly, an evaluation of controls cannot provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.

**Evaluation of Disclosure Controls and Procedures**

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) for the quarter ended March 31, 2026. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of such time due to the material weakness described below.

In making such conclusion, our management determined that such deficiencies were determined to be material weaknesses that are primarily due to certain staff reductions and voluntary resignations we experienced beginning in the fourth quarter of 2020 and continuing through the date of this filing. During such periods and for all periods thereafter through the date of such determination, we increased our reliance on outsourced accounting help. As a result of such changes, our management concluded that we were unable to maintain the levels of resources during such periods at the levels of prior periods, and that such changes to our procedures significantly affected our internal control over financial reporting during the quarter ended March 31, 2026.

------

**Changes in Internal Control over Financial Reporting**

There was no change in the Company's internal control over financial reporting during the most recent three-month period covered by this Quarterly Report that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21

------

**PART II. OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

Except as described in Note 9 - Commitments and Contingencies, there were no material developments during the quarter ended March 31, 2026 in the legal proceedings described in our Annual Report on Form 10-K for the year ended December 31, 2025

**ITEM 1A. RISK FACTORS**

There were no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

**ITEM *5.* OTHER INFORMATION**

None.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *22*

------

**ITEM 6. EXHIBITS**

A list of exhibits is set forth at the end of this Quarterly Report for the information required by this item.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | | **Incorporated by Reference** | **Incorporated by Reference** | |  |
| <br>**Exhibit**<br> **Number** | <br>**Exhibit Description** | <br>**Form** | **File No.** | **Exhibit** | <br>**Filing**<br> **Date** | **Filed**<br> **Herewith** |
| 3.1 | [Amended and Restated Certificate of Incorporation of the Company](http://www.sec.gov/Archives/edgar/data/1563568/000119312517204138/d404647dex1a15addexhb.htm) | 1-A POS | 024-10656 | 2.7 | 6/15/2017 |  |
| 3.2 | [<u>Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company</u> <u>filed with the Secretary of State of Delaware on June 8, 2018</u>](http://www.sec.gov/Archives/edgar/data/1563568/000117184318004584/exh_31.htm) | 8-K | 001-38078 | 3.1 | 6/11/2018 |  |
| 3.3 | [<u>Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company</u> <u>filed with the Secretary of State of Delaware on May 26, 2021</u>](http://www.sec.gov/Archives/edgar/data/1563568/000156459021031420/adom-ex31_7.htm) | 8-K | 001-38078 | 3.1 | 6/2/2021 |  |
| 3.4 | [<u>Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company</u> <u>filed with the Secretary of State of Delaware on June 24, 2022</u>](http://www.sec.gov/Archives/edgar/data/1563568/000119312522184040/d367993dex31.htm) | 8-K | 001-38078 | 3.1 | 6/28/2022 |  |
| 3.5 | [<u>Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company filed with the Secretary of State of Delaware on August 6, 2025</u>](http://www.sec.gov/Archives/edgar/data/1563568/000143774925024973/ex_848336.htm) | 8-K | 001-38078 | 3.1 | 8/6/2025 |  |
| 3.6 | [Amended and Restated Bylaws of the Company](http://www.sec.gov/Archives/edgar/data/1563568/000119312517204138/d404647dex1a2bbylaws.htm) | 1-A POS | 024-10656 | 2.8 | 6/15/2017 |  |
| 10.1 | [<u>Securities Purchase Agreement, dated as of March 6, 2026, between Envirotech Vehicles, Inc. and the investor listed on Schedule I thereto</u>](http://www.sec.gov/Archives/edgar/data/1563568/000143774926007368/ex_929834.htm) | 8-K | 001-38078 | 10.1 | 3/9/2026 |  |
| 10.2 | [Envirotech Vehicles, Inc. 2017 Equity Incentive Plan, as amended.](http://www.sec.gov/Archives/edgar/data/1563568/000143774925035469/adom20251114_def14a.htm#appendixa) | DEF14A | 001-38078 | Appendix A | 11/17/2025 |  |
| 31.1 | [Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer](ex_912387.htm) |  |  |  |  | X |
| 31.2 | [Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer](ex_912388.htm) |  |  |  |  | X |
| 32.1# | [18 U.S.C. Section 1350 Certification of Chief Executive Officer, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex_912389.htm) |  |  |  |  | X |
| 32.2# | [18 U.S.C. Section 1350 Certification of Chief Financial Officer, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex_912390.htm) |  |  |  |  | X |
| 101.INS | Inline XBRL Instance Document\* |  |  |  |  | X |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document\* |  |  |  |  | X |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document\* |  |  |  |  | X |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document\* |  |  |  |  | X |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document\* |  |  |  |  | X |
| 101.DEF | Inline XBRL Taxonomy Extension Definitions Linkbase Document\* |  |  |  |  | X |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). |  |  |  |  |  |

---

# The information in Exhibits 32.1 and 32.2 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference.

\* In accordance with Rule 402 of Regulation S-T, this interactive data file is deemed not filed or part of this Quarterly Report for purposes of Sections 11 or 12 of the Securities Act or Section 18 of the Exchange Act and otherwise is not subject to liability under these sections.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Envirotech Vehicles, Inc. | Envirotech Vehicles, Inc. |
| Date: May 19, 2026 | By: | /s/ Phillip W. Oldridge |
|  |  | Phillip W. Oldridge |
|  |  | Chief Executive Officer |
|  |  | (Principal Executive Officer) |
| Date: May 19, 2026 | By: | /s/ Jason Maddox |
|  |  | Jason Maddox |
|  |  | President and Interim Chief Financial Officer |
|  |  | (Principal Financial and Accounting Officer) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24

## Exhibit 31.1

**Exhibit 31.1**

**Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934**

I, Phillip W. Oldridge, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly Report on Form 10-Q of Envirotech Vehicles, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 19, 2026

By: <u>/s/ Phillip W. Oldridge</u> 

Phillip W. Oldridge

Chief Executive Officer

(Principal Executive Officer)

## Exhibit 31.2

**Exhibit 31.2**

**Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act Of 1934**

I, Jason Maddox, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly Report on Form 10-Q of Envirotech Vehicles, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 19, 2026

By: <u>/s/ Jason Maddox</u> 

Jason Maddox

President and Interim Chief Financial Officer

(Principal Financial Officer)

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350**

In connection with the Quarterly Report of Envirotech Vehicles, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Phillip W. Oldridge, Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 19, 2026

By: <u>/s/ Phillip W. Oldridge</u> 

Name Phillip W. Oldridge

Title: Chief Executive Officer

(Principal Executive Officer)

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification will not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that Section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.

## Exhibit 32.2

**9Exhibit 32.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350**

In connection with the Quarterly Report of Envirotech Vehicles, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jason Maddox, President and Interim Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 19, 2026

By: <u>/s/ Jason Maddox</u> 

Jason Maddox

President and Interim Chief Financial Officer

(Principal Financial Officer)

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification will not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that Section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.